Nacuity Pharmaceuticals is a clinical-stage leader in innovative treatments for oxidative stress. The company's powerful, targeted therapies aim to stop oxidative tissue damage, a driver of blinding eye diseases and a broad spectrum of serious chronic conditions. Nacuity has three highly differentiated clinical programs ongoing in retinitis pigmentosa, cataracts and cystinosis with the potential to be first-of-a-kind therapies and gateways to wider applications.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 06/15/22 | $16,500,000 | Series B |
RD Fund | undisclosed |
